CSIMarket Company Name, Ticker, Industry, else..
 
Calidi Biotherapeutics Inc   (CLDI)
Other Ticker:  
 
 
Price: $1.0600 $-0.02 -1.852%
Day's High: $1.08 Week Perf: -7.02 %
Day's Low: $ 1.02 30 Day Perf: -7.02 %
Volume (M): 59 52 Wk High: $ 2.63
Volume (M$): $ 63 52 Wk Avg: $0.90
Open: $1.08 52 Wk Low: $0.14



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 1

Calidi Biotherapeutics Inc
Calidi Biotherapeutics Inc is a biotechnology company that focuses on developing innovative cellular therapies for cancer treatment. They specialize in utilizing the power of oncolytic viruses to target and destroy cancer cells while preserving healthy cells. By engineering the viruses to specifically target tumors, Calidi Biotherapeutics aims to provide effective and personalized cancer treatments with minimal side effects. Their research and development efforts are centered around creating novel therapies that can potentially revolutionize cancer treatment and improve patient outcomes.


   Company Address: 4475 Executive Drive San Diego 92121 CA
   Company Phone Number: 794-9600   Stock Exchange / Ticker: NYSE CLDI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Advancing Hope in High-Grade Glioma Treatment FDA Clearance of CLD-101 Clinical Trial by Calidi Biotherapeutics

Published Mon, Sep 30 2024 12:00 PM UTC

In an exciting development for the realm of neuro-oncology, Calidi Biotherapeutics has announced FDA clearance for its Investigational New Drug (IND) application for CLD-101, a promising treatment aimed at newly diagnosed high-grade glioma. This decision reflects a critical milestone not only for the company but also for patients grappling with one of the deadliest forms of ...
Financing Agreement

Calidi Biotherapeutics Receives Financial Boost to Revolutionize Cancer Therapies

Published Mon, Jul 29 2024 1:00 PM UTC

Calidi Biotherapeutics Secures $3 Million Investment from Dr. Ronald Rigor for Nova Cell Subsidiary Development and Oncology Pipeline Expansion
San Diego-based biotechnology company, Calidi Biotherapeutics, has announced a strategic investment of $2 million from Dr. Ronald Rigor into its newly established subsidiary, Nova Cell, Inc. This investment is intended to acceler...
Management Changes

Dr. Mark Gilbert Joins Calidi Biotherapeutics' Medical Advisory Board, Bringing In-Depth Government Healthcare Agency Expertise

Published Tue, Jul 16 2024 12:00 PM UTC


Introduction
In a recent press release, Calidi Biotherapeutics Inc, a leading biopharmaceutical company focused on developing innovative cell-based immunotherapies, announced the appointment of Dr. Mark Gilbert to its esteemed Medical Advisory Board. Dr. Gilbert, a former neuro-oncology leader at the renowned National Institutes of Health (NIH) and National Cancer I...
Calidi Biotherapeutics Inc

Headline: Company Sees Increase in Business Expenditures during Q1 2024

The financial results of Calidi Biotherapeutics Inc for the January to March 31, 2024 reporting season have not been favorable to stockholders. The company's revenue did not see any adjustments during this time period, but the operating loss increased to $-6.752 million. This was not well-received by investors, who are eagerly awaiting a new business strategy from the company.
During this challenging period, Calidi Biotherapeutics Inc experienced a net loss of $-7.225 million, further dampening the outlook for the company. This has caused concern among shareholders, who are no longer relying on the organizational and operational excellence of the company.
Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc Reports Operating Deficit of $-18.2 Million in Fourth Quarter of 2023

In the world of biotechnology and pharmaceuticals, Calidi Biotherapeutics Inc has recently announced its financial results for the fourth quarter of 2023. The company reported an operating deficit of $-18.246049 million, a significant increase from the operating deficit of $-2.714765 million in the fourth quarter of 2022.
The net deficit for the financial period ending December 31, 2023, was reported at $-20.699 million, a substantial increase from $-2.587 million in the previous year. Despite these losses, the company did not report any revenue for the financial year 2023, with a bottom-line of $-29.22 million.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com